Zymeworks ROE 2016-2022 | ZYME

Current and historical return on equity (ROE) values for Zymeworks (ZYME) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Zymeworks ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-03-31 $-0.24B $0.28B -85.23%
2021-12-31 $-0.21B $0.25B -69.49%
2021-09-30 $-0.21B $0.28B -61.14%
2021-06-30 $-0.22B $0.32B -58.18%
2021-03-31 $-0.20B $0.38B -45.61%
2020-12-31 $-0.18B $0.41B -39.03%
2020-09-30 $-0.22B $0.43B -50.86%
2020-06-30 $-0.17B $0.49B -43.85%
2020-03-31 $-0.16B $0.52B -45.89%
2019-12-31 $-0.15B $0.25B -54.72%
2019-09-30 $-0.06B $0.31B -25.75%
2019-06-30 $-0.05B $0.33B -24.82%
2019-03-31 $-0.03B $0.17B -17.00%
2018-12-31 $-0.04B $0.18B -23.45%
2018-09-30 $-0.01B $0.17B -9.17%
2018-06-30 $-0.01B $0.19B -8.33%
2018-03-31 $-0.02B $0.10B -15.35%
2017-12-31 $-0.01B $0.12B -11.56%
2017-09-30 $-0.05B $0.08B -72.48%
2017-06-30 $-0.05B $0.10B -93.02%
2017-03-31 $-0.05B $0.05B -155.93%
2016-12-31 $-0.03B $0.07B -194.12%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.320B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00